ATE529432T1 - Azazyklosteroid als ligande der histamin-3 rezeptoren - Google Patents

Azazyklosteroid als ligande der histamin-3 rezeptoren

Info

Publication number
ATE529432T1
ATE529432T1 AT05738987T AT05738987T ATE529432T1 AT E529432 T1 ATE529432 T1 AT E529432T1 AT 05738987 T AT05738987 T AT 05738987T AT 05738987 T AT05738987 T AT 05738987T AT E529432 T1 ATE529432 T1 AT E529432T1
Authority
AT
Austria
Prior art keywords
histamine
azazyklosteroid
receptors
ligand
compounds
Prior art date
Application number
AT05738987T
Other languages
English (en)
Inventor
Chen Zhao
Minghua Sun
Marlon Cowart
Youssef Bennani
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE529432T1 publication Critical patent/ATE529432T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
AT05738987T 2004-04-07 2005-04-06 Azazyklosteroid als ligande der histamin-3 rezeptoren ATE529432T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/819,849 US20050245495A1 (en) 2004-04-07 2004-04-07 Azacyclosteroid histamine-3 receptor ligands
PCT/US2005/014019 WO2005100377A1 (en) 2004-04-07 2005-04-06 Azacyclosteroid histamine-3 receptor ligands

Publications (1)

Publication Number Publication Date
ATE529432T1 true ATE529432T1 (de) 2011-11-15

Family

ID=34966577

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05738987T ATE529432T1 (de) 2004-04-07 2005-04-06 Azazyklosteroid als ligande der histamin-3 rezeptoren

Country Status (8)

Country Link
US (1) US20050245495A1 (de)
EP (1) EP1735332B1 (de)
JP (1) JP5006779B2 (de)
AT (1) ATE529432T1 (de)
CA (1) CA2562189C (de)
ES (1) ES2372604T3 (de)
MX (1) MXPA06011669A (de)
WO (1) WO2005100377A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100040568A1 (en) * 2008-04-30 2010-02-18 Skinmedica, Inc. Steroidal compounds as melanogenesis modifiers and uses thereof
CN102137673A (zh) * 2008-04-30 2011-07-27 纽约大学 作为黑素生成调节剂的甾族化合物及其用途
FR2994092B1 (fr) * 2012-08-03 2014-11-28 Centre Nat Rech Scient Nouveaux composes activateurs de l'activite enzymatique de sirt1 et compositions pharmaceutiques ou cosmetiques les comprenant
CN103193857B (zh) * 2013-03-31 2014-12-24 兰州理工大学 止泻木生物碱衍生物及其用途
CN108264535A (zh) * 2016-12-30 2018-07-10 中国科学院上海药物研究所 一种抗抑郁化合物及其制备方法和应用
EP4192247A1 (de) * 2020-08-04 2023-06-14 Harrow IP, LLC Antibakterielle zusammensetzungen und verfahren zur herstellung davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063987A (en) * 1959-06-16 1962-11-13 Searle & Co 18-dimethylamino steroids and intermediates
US3152120A (en) * 1959-09-30 1964-10-06 Smith Kline French Lab Process for the preparation of conanine derivatives and novel derivatives prepared thereby
NL124636C (de) * 1965-02-26
BE672238A (de) * 1965-11-12 1966-03-01
BE687512A (de) * 1966-09-28 1967-03-01
NL6908367A (de) * 1969-01-16 1970-07-20 Koninklijke Gist Spiritus

Also Published As

Publication number Publication date
EP1735332A1 (de) 2006-12-27
EP1735332B1 (de) 2011-10-19
CA2562189C (en) 2012-12-04
MXPA06011669A (es) 2007-01-23
CA2562189A1 (en) 2005-10-27
JP5006779B2 (ja) 2012-08-22
ES2372604T3 (es) 2012-01-24
WO2005100377A1 (en) 2005-10-27
US20050245495A1 (en) 2005-11-03
JP2007532583A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
LTC1725537I2 (lt) Nauji junginiai, kaip opioido receptoriaus moduliatoriai
DK1888541T3 (da) Benzo(d)isoxazol-3-yl-amin-forbindelser og anvendelse af disse som vanilloidreceptorligander
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
DK1802307T3 (da) Pyrrolidinderivater som histamin-receptor-ligander
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
TR200300322T2 (tr) Kemokin alıcısını bağlayan heterosiklik bileşikler
CY1111729T1 (el) Υπογλωσσιο επικαλυμμενο δισκιο
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
DE602005008855D1 (de) Dichtung, die grosse Radialbewegungen zulässt
ATE383857T1 (de) Als histamin-3-rezeptorliganden einsetzbare naphthalene-derivate
ATE469895T1 (de) Cgrp-rezeptorantagonisten
ATE473744T1 (de) Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren
DE602006016303D1 (de) 3,4-dihydro-2H-benzoÄ1,4Üoxazin- und 3,4-dihydro-2H-benzoÄ1,4Üthiazin-VERBINDUNGEN ALS ALPHA2C-ADRENOREZEPTOR-ANTAGONISTEN
TW200800967A (en) Benzimidazole thiophene compounds
EA200801414A1 (ru) Кальцилитические соединения
ATE529432T1 (de) Azazyklosteroid als ligande der histamin-3 rezeptoren
DK1636221T3 (da) 3-Heterocyclyl-azetidin-forbindelser, som er nytte som NK1/NK2 receptorantagonister
WO2006047269A3 (en) Pharmaceutical compositions
FI20041129A0 (fi) Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
WO2007024744A3 (en) Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
UY30801A1 (es) Compuestos calciliticos
ATE478845T1 (de) Pyrrolidiniumderivative als liganden für den muscarinen m3-rezeptor
DE602004014773D1 (de) Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties